Biotech Values

[jq1234]

>> Long-term durability with price - With a rational Merck, what Gilead may have done is just accelerate the lowering of price from a 3 year endeavor to a 4-6 month endeavor.


Great rationalization from analysts on why they didn't see this type of sharp price cutting coming, oh, it was because someone else was not rational, not because they couldn't see HCV market dynamics clearly. I'll save this report, show how stupid their assumptions are a few years down the road, just like those famous CS reports at the end of 2013 on how high HCV drug prices would be in the future!